Choose a Drug ! Aciphex Acomplia Actos Acyclovir Allegra Alli Diet Drug Altace Ambien Amoxicillin Atenolol Ativan Augmentin Avandia Avapro Baclofen Bactrim Biaxin Celebrex Celexa Cephalexin Champix Cialis Cipro Claritin D Clomid Coreg Depakote Diflucan Dilantin Diovan Doxycycline Effexor XR Elavil Estradiol Flomax Flonase Fluoxetine Folic Acid Fosamax Glucophage Hydroxyzine Ibuprofen Imitrex Keflex Lamisil Lasix Levaquin Levitra Lexapro Lipitor Mobic Naproxen Neurontin Nexium Norvasc Omeprazole Paxil Plavix Premarin Prevacid Promethazine Propecia Proscar Protonix Reductil Reglan Remeron Risperdal Singulair Sonata Synthroid Tamiflu Topamax Trazodone Ultra "C" tabs Ultra "L" tabs Ultra "V" tabs Ultram Viagra Wellbutrin Xenical Zithromax Zocor Zoloft Zyban Zyprexa Zyrtec

September 2007 August 2007 July 2007 June 2007 May 2007 April 2007 March 2007 February 2007 January 2007 December 2006 November 2006 October 2006 September 2006 August 2006 July 2006 June 2006 May 2006 April 2006 March 2006 February 2006

Opt-in for Free Newsletter, special discount offers, drugs information & latest pharmacy news.

Lilly To Churn Better Sales from Once-Daily Cialis

Having won approval to market a one-a-day version of prolific erectile-dysfunction drug Cialis in the Europe, Eli Lilly and Co. is all set to overtake other leading brands specifically Viagra and levitra, together with the fact that neither Viagra nor levitra is marketed in once a daily version, which would lend an edge to the pill above all. Furthermore, the company is also hopeful of getting the U.S. approval later this year.

The once-a-day Cialis is explicitly marketed for men who want to have sex thrice or more times with in a week. While Viagra and other leading ED drugs such as Levitra, work only for four hours, Cialis works up to 36 hours. Though Cialis stands behind its rival Viagra in the U.S,, but it is on the top position in other 22 nations, right from France to Mexico, in to the $3 billion global market for erectile dysfunction.

The once-daily version also works in the same manner, by jamming the action of an enzyme in men’s body to attain and uphold an erection.

If doctors’ say is to be considered, once-a-day version of Cialis will top the sales chart.   “I think a certain group of patient may reap most out of the pill to be ready at any time," said Dr. Ronald Suh from Urology of Indiana.

While on the other, some analysts believes that once-a-day version might boost Lilly sales, but only in the modest way. Yet, it can’t be denied that it might offer a more stable revenue flow than the present dose of Cialis, which is used sporadically by men.

Meanwhile, the company still hopes to make it in the global drug market.

“Right from its launch in 2003, Cialis has gained market share every quarter and any sustained improvement in its results is likely to help the bottom line at Lilly”, Lilly said.

Lilly anticipates that Cialis sales will reach the mark of $1 billion this year, proffering it the status of best-seller.

According to IMS Heath, Cialis' U.S. market share has shot up from 14 percent (in the 2003) to 27 percent in the last year, whereas Viagra's fell down from 73 percent to 56 percent in the same duration.